Cargando…

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?

Detalles Bibliográficos
Autores principales:	Eloy, Philippine, Le Grand, Roger, Malvy, Denis, Guedj, Jérémie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577853/ https://www.ncbi.nlm.nih.gov/pubmed/34768087 http://dx.doi.org/10.1016/j.ebiom.2021.103663

Ejemplares similares

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea
por: Eloy, Philippine, et al.
Publicado: (2022)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2
por: Dömötör, Orsolya, et al.
Publicado: (2023)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
por: Madelain, Vincent, et al.
Publicado: (2020)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin
por: Lingas, Guillaume, et al.
Publicado: (2021)

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
por: Holman, Wendy, et al.
Publicado: (2021)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Commentary: One plus one does not always equal two: Mitochondrial cardioprotection
por: Guariento, Alvise, et al.
Publicado: (2021)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

The Role of Antibody Testing for SARS-CoV-2: Is There One?
por: Theel, Elitza S., et al.
Publicado: (2020)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017)

Zéro: ou les cinq vies d'Aémer
por: Guedj, Denis
Publicado: (2005)

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
por: Guedj, Jérémie, et al.
Publicado: (2018)

Commentary: Destination zero stroke: Three steps, but one at a time
por: Tatoulis, James
Publicado: (2021)

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers
por: Malvy, Denis, et al.
Publicado: (2020)

A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy d glucose in treating COVID-19
por: Kulkarni, Prajakta, et al.
Publicado: (2022)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
por: Gordon, Calvin J., et al.
Publicado: (2021)

Molnupiravir for SARS-CoV-2 infection: Public health and policy implications
por: Gray, Edward J., et al.
Publicado: (2023)

One year of SARS-CoV-2 evolution
por: Wu, Aiping, et al.
Publicado: (2021)

Commentary: The great equalizer
por: Ceppa, DuyKhanh P.
Publicado: (2022)

Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
por: Johnson, Dylan M., et al.
Publicado: (2023)

Justice and equality as a zero-sum game
por: Hellman, Matilda
Publicado: (2022)

Towards zero rate in healthcare-associated infections: one size shall not fit all...
por: Lisboa, Thiago, et al.
Publicado: (2013)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
por: Sanderson, Theo, et al.
Publicado: (2023)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
por: Gonçalves, Antonio, et al.
Publicado: (2020)

One zero show : spectacle arithmétique en 0 acte et 1 tableau... blanc ; suivi de Du point... à la ligne : spectacle géométrique en ligne... et en surface
por: Guedj, Denis
Publicado: (2001)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

To DNA, all information is equal
por: Sennels, Lau, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p69pmc8vbt0nom3prs1d1m6dfm